[FMS] Fresenius Medical Care Thesis 2026: Care Enablement Margin Cycle Drives US Dialysis Recovery
Fresenius Medical Care AG (NYSE: FMS) FY2025 revenue ~€19.5-20.5B (~$21-22B; +0-5%) with adj. EPS ~€2.40-2.80 (~$1.30-1.50 per ADR) reflecting continued post-2024 ~340,000+ aggregate dialysis patients globally + selected continued post-2024 ~$15-16B aggregate Care Delivery revenue (~75%+ aggregate revenue mix; selected primary US + selected various international dialysis services) + selected continued post-2024 ~$5-5.5B aggregate Care Enablement revenue (~25% aggregate revenue mix; selected primary dialysis products + selected various) + selected post-November 2022 selected various FME25 ~$0.7B aggregate cumulative cost savings program completion + selected continued post-November 2022 selected various Helen Giza turnaround under continued President + CEO Helen Giza since November 2022 (~3-year tenure as Fresenius Medical Care CEO). The world's largest dialysis services + dialysis products company. Founded 1996 as Fresenius Medical Care AG via 1996 Fresenius AG + National Medical Care merger; selected post-1912 Fresenius founding heritage; selected post-1996 NYSE ADR listing; selected post-November 2022 Helen Giza CEO appointment + FME25 program. Headquartered in Bad Homburg Germany; ~120,000+ employees globally with ~€19.5-20.5B revenue. Two primary business segments: Care Delivery (~75%+ ~€15-16B), Care Enablement (~25% ~€5-5.5B). Geographic mix: US ~55%+ + EMEA ~25% + LatAm + APAC ~20%. US dialysis cycle + Care Delivery: ~340,000+ aggregate dialysis patients; ~37%+ aggregate US dialysis market share alongside DaVita ~37%+. Care Enablement margin cycle: ~13-15% Care Enablement operating margin trajectory toward ~15-17%; FME25 ~$0.7B cumulative cost savings completion. President + CEO Helen Giza since November 2022 (~3-year tenure); CFO Martin Fischer. Capital return: ~€1.44 annual dividend FY2025 (~+5-10% growth; ~25-year continuous dividend track); modest opportunistic buybacks; aggregate capital return ~€0.4-0.5B; net leverage ratio ~3.0-3.5x; investment-grade Baa3/BBB credit rating. FY2026 thesis: US dialysis Care Delivery cycle + Care Enablement margin recovery + selected continued post-November 2022 FME25 turnaround + ~€1.44 annual dividend + ~25-year continuous dividend track + ~€0.4-0.6B aggregate annual capital return + selected continued post-November 2022 deleveraging + selected potential post-deleveraging dividend acceleration. Risks: US dialysis reimbursement risk, DaVita competition, FME25 turnaround execution, US Medicare + international reimbursement, EUR/USD volatility.
[FMS] Fresenius Medical Care Thesis 2026: Care Enablement Margin Cycle Drives US Dialysis Recovery
Key Takeaways
- Fresenius Medical Care AG (NYSE: FMS) FY2025 revenue
€19.5-20.5B ($21-22B; +0-5% YoY) with adj. EPS€2.40-2.80 ($1.30-1.50 per ADR) reflecting continued post-2024 ~340,000+ aggregate dialysis patients globally + selected continued post-2024 ~$15-16B aggregate Care Delivery revenue (~75%+ aggregate revenue mix; selected primary US + selected various international dialysis services) plus selected continued post-2024 ~$5-5.5B aggregate Care Enablement revenue (~25% aggregate revenue mix; selected primary dialysis products + selected various) plus selected post-November 2022 selected various FME25 ~$0.7B aggregate cumulative cost savings program completion + selected continued post-November 2022 selected various Helen Giza turnaround under continued President + CEO Helen Giza since November 2022 (~3-year tenure as Fresenius Medical Care CEO; ex-Fresenius Medical Care CFO 2019-2022 + ex-Tate & Lyle CFO + ex-various roles + ~30-year industry career; succeeded post-November 2022 Rice Powell retirement). - US dialysis cycle + Care Delivery: ~$15-16B aggregate Care Delivery revenue FY2025 (~75%+ aggregate revenue mix); selected continued post-2024 ~340,000+ aggregate dialysis patients globally; selected continued post-2024 ~$10-11B aggregate US Care Delivery (selected primary US dialysis services market leadership; selected ~37%+ aggregate US dialysis market share alongside DaVita
37%+); selected continued post-2024 selected various International Care Delivery ($4-5B; selected primary Europe + Asia + Latin America); selected continued post-2024 ~$0.20-0.30 incremental annual EPS contribution. - Care Enablement margin cycle: ~$5-5.5B aggregate Care Enablement revenue FY2025 (~25% aggregate revenue mix; selected primary dialysis products + selected various); selected continued post-November 2022 FME25 ~$0.7B aggregate cumulative cost savings program completion (selected post-November 2022 turnaround); selected continued post-2024 selected ~13-15% aggregate Care Enablement operating margin trajectory toward selected ~15-17%; selected continued post-2024 ~$0.10-0.20 incremental annual EPS contribution.
- Capital return:
€1.44 annual dividend FY2025 (€0.36/quarter; selected post-2024 ~+5-10% growth post-2024 ~€1.31 dividend; selected ~25-year continuous dividend track post-1998 Fresenius Medical Care formation); selected modest opportunistic buybacks; ~€0.4-0.5B aggregate FY2025 capital return; selected post-2024 net leverage ratio ~3.0-3.5x net debt-to-adj. EBITDA target (selected post-November 2022 turnaround deleveraging); investment-grade Baa3/BBB credit rating; FY2026 catalyst: continued capital return + selected potential post-deleveraging dividend acceleration.
Company Background
Fresenius Medical Care AG (NYSE: FMS) is the world's largest dialysis services + dialysis products company with FY2025 revenue €19.5-20.5B ($21-22B; +0-5% YoY) and adj. EPS €2.40-2.80 ($1.30-1.50 per ADR) reflecting continued post-2024 ~340,000+ aggregate dialysis patients globally + selected continued post-2024 ~$15-16B aggregate Care Delivery revenue + selected continued post-2024 ~$5-5.5B aggregate Care Enablement revenue + selected post-November 2022 selected various FME25 ~$0.7B aggregate cumulative cost savings program completion. The company employs ~120,000+ globally with operations across selected major Bad Homburg Germany + Waltham Massachusetts + Charlotte North Carolina + selected various 150+ countries.
Founded 1996 as Fresenius Medical Care AG via 1996 Fresenius AG + National Medical Care merger (selected post-1996 closing creating world's largest dialysis services + dialysis products company); selected post-1996 NYSE ADR listing transition; selected post-1912 Fresenius founding heritage of 1912 Hirschapotheke pharmacy predecessor in Bad Homburg Germany; selected post-1996-2018 ~$10B+ aggregate selected various dialysis services + selected various dialysis products M&A platform expansion (selected ~$3.6B Bio-Medical Applications + selected various Renal Care Group + selected various NxStage); selected post-November 2022 Helen Giza CEO appointment (selected post-Rice Powell retirement); selected post-November 2022 selected FME25 ~$0.7B aggregate cumulative cost savings program initiation + selected various turnaround; selected post-2023 selected various FME25 cost savings completion + selected various Care Enablement margin recovery + selected various Care Delivery + selected various international restructuring.
Headquartered in Bad Homburg Germany (with Waltham Massachusetts + Charlotte North Carolina selected major US offices); ~120,000+ employees globally with ~€19.5-20.5B revenue. Two primary business segments: Care Delivery (~75%+ revenue ~€15-16B — selected primary US dialysis services + selected various International dialysis services), Care Enablement (~25% revenue ~€5-5.5B — selected primary dialysis products + selected various). Geographic mix: US 55%+ revenue (€11-12B — primary US dialysis services + selected various Care Enablement) + Europe + Middle East + Africa 25% (€5B) + Latin America + Asia Pacific 20% (€4B).
President + CEO Helen Giza since November 2022 (~3-year tenure as Fresenius Medical Care CEO); succeeded Rice Powell (CEO 2013-November 2022 retired who led Fresenius Medical Care through post-2013 selected various US dialysis services expansion); Giza ex-Fresenius Medical Care CFO 2019-2022 + ex-Tate & Lyle CFO + ex-various roles + ~30-year industry career; selected continued strategic priorities include US dialysis Care Delivery leadership + selected continued post-November 2022 FME25 cost savings + selected continued post-2024 Care Enablement margin recovery + selected continued post-2024 selected various International Care Delivery + selected continued post-November 2022 deleveraging + selected continued post-2024 capital return acceleration. CFO Martin Fischer (since 2022; ex-Fresenius SE CFO + ex-various roles + ~25-year industry career).
US Dialysis Cycle + Care Delivery
Fresenius Medical Care US dialysis Care Delivery franchise:
- Care Delivery revenue:
75%+ aggregate revenue (€15-16B) - Aggregate dialysis patients globally: ~340,000+
- US Care Delivery: ~$10-11B aggregate (selected primary US dialysis services)
- US dialysis market share: selected ~37%+ aggregate US dialysis market share alongside DaVita ~37%+
- International Care Delivery: ~$4-5B aggregate (selected primary Europe + Asia + Latin America)
- Selected continued post-2024 ~$0.20-0.30 incremental annual EPS contribution: continued post-2024
FY2026 catalyst: continued US dialysis cycle + Care Delivery + ~$0.20-0.30 incremental annual EPS contribution.
Care Enablement Margin Cycle
Fresenius Medical Care Care Enablement franchise:
- Care Enablement revenue:
25% aggregate revenue (€5-5.5B) - Dialysis products: selected primary dialysis products + selected various
- FME25 cost savings: post-November 2022 FME25 ~$0.7B aggregate cumulative cost savings program completion
- Care Enablement operating margin trajectory: selected ~13-15% aggregate Care Enablement operating margin trajectory toward selected ~15-17%
- Selected continued post-2024 ~$0.10-0.20 incremental annual EPS contribution: continued post-2024
FY2026 catalyst: continued Care Enablement margin recovery + ~$0.10-0.20 incremental EPS contribution.
Capital Return + Deleveraging
Fresenius Medical Care capital return policy targets continued post-November 2022 deleveraging + dividend stability:
- Ordinary dividend:
€1.44 annual FY2025 (€0.36/quarter; selected post-2024 ~+5-10% growth post-2024 ~€1.31 dividend; selected ~25-year continuous dividend track post-1998 Fresenius Medical Care formation) - Buybacks: selected modest opportunistic buybacks
- Aggregate capital return: ~€0.4-0.5B FY2025
- Net leverage: net debt-to-adj. EBITDA ~3.0-3.5x FY2025 (selected post-November 2022 turnaround deleveraging)
- Investment grade: Baa3/BBB credit rating
FY2026 catalyst: continued capital return + selected potential post-deleveraging dividend acceleration.
Risks
- US dialysis market cycle: continued post-2024 US dialysis services + selected various reimbursement risk
- Selected various competitive intensity: DaVita + selected various US dialysis + selected various dialysis products + selected various competitive
- Selected post-November 2022 FME25 turnaround: continued post-November 2022 FME25 turnaround execution
- Selected various reimbursement: continued post-2024 US Medicare + selected various international reimbursement risk
- Selected various FX: continued EUR/USD + selected various FX volatility
Key Core Metrics
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2026 outlook |
|---|---|---|---|---|---|
| Revenue | €19.5-20.5B | €19.40B | €19.45B | €19.40B | €20.0-21.0B |
| Adj. EBITDA | €2.50-2.75B | €2.40B | €2.10B | €2.10B | €2.65-2.90B |
| Adj. EPS (EUR) | €2.40-2.80 | €2.20 | €1.85 | €1.85 | €2.65-3.05 |
| Adj. EBITDA margin | 13-13% | 12% | 11% | 11% | 13-14% |
| Patients (K) | 340+ | 330 | 322 | 345 | 345+ |
| Capital + cash | FY2025 | FY2024 | FY2026 outlook |
|---|---|---|---|
| Dividend (EUR) | €1.44 | €1.31 | €1.55-1.70 |
| Buybacks | modest | modest | modest |
| Total return | €0.4-0.5B | €0.4B | €0.5-0.6B |
| Net leverage | 3.0-3.5x | 3.3x | 2.7-3.2x |
Market Evaluation
Fresenius Medical Care trades at selected ~10-13x FY2026 P/E discount vs DaVita (~13-16x) + selected various US + global dialysis + dialysis products peers reflecting selected continued ~340,000+ aggregate dialysis patients globally + selected continued post-2024 ~$15-16B aggregate Care Delivery + selected post-November 2022 FME25 ~$0.7B aggregate cumulative cost savings program completion + selected ~25-year continuous dividend track + selected continued post-2024 ~3.0-3.5x net leverage. Selected re-rating catalysts include: (1) continued US dialysis Care Delivery + ~37%+ aggregate US dialysis market share leadership; (2) selected continued post-November 2022 FME25 turnaround + Care Enablement margin recovery toward ~15-17%; (3) ~€1.44 dividend + ~+5-10% growth + selected ~25-year continuous dividend track; (4) ~€0.4-0.6B aggregate annual capital return; (5) selected continued post-November 2022 deleveraging toward ~2.7-3.2x.
Care Delivery + FME25 Strategic Differentiation Deep Dive
Fresenius Medical Care US dialysis Care Delivery franchise + selected post-November 2022 selected various FME25 ~$0.7B aggregate cumulative cost savings program completion + selected continued post-November 2022 selected various Helen Giza turnaround represent selected primary strategic differentiation thesis vs traditional US + global dialysis + dialysis products peers (DaVita + selected various). Selected ~$15-16B aggregate Care Delivery revenue FY2025 (~75%+ aggregate revenue mix; selected primary US + selected various international dialysis services) + selected continued post-2024 ~340,000+ aggregate dialysis patients globally + selected ~$10-11B aggregate US Care Delivery (selected primary US dialysis services market leadership; selected ~37%+ aggregate US dialysis market share alongside DaVita ~37%+) + selected continued post-2024 ~$4-5B aggregate International Care Delivery (selected primary Europe + Asia + Latin America) supports selected primary US dialysis Care Delivery thesis. Selected continued post-2024 ~$5-5.5B aggregate Care Enablement revenue (~25% aggregate revenue mix; selected primary dialysis products + selected various) + selected post-November 2022 FME25 ~$0.7B aggregate cumulative cost savings program completion + selected continued post-2024 selected ~13-15% aggregate Care Enablement operating margin trajectory toward selected ~15-17% + selected continued post-2024 ~$0.10-0.20 incremental annual EPS contribution supports selected continued post-November 2022 Care Enablement margin recovery thesis. Selected ~€1.44 annual dividend FY2025 (selected post-2024 ~+5-10% growth post-2024 ~€1.31 dividend; selected ~25-year continuous dividend track post-1998 Fresenius Medical Care formation) + selected modest opportunistic buybacks + selected post-November 2022 ~3.0-3.5x net leverage ratio supports selected continued post-2024 capital return optionality. Selected post-November 2022 Helen Giza CEO appointment (selected ex-Fresenius Medical Care CFO 2019-2022 + ~30-year industry career) supports selected continued post-November 2022 strategic priorities. FY2026 catalyst: continued Care Delivery + Care Enablement + ~$0.20-0.30 incremental annual EPS contribution.
FY2026 thesis: US dialysis Care Delivery cycle + Care Enablement margin recovery + selected continued post-November 2022 FME25 turnaround + ~€1.44 annual dividend + ~25-year continuous dividend track + ~€0.4-0.6B aggregate annual capital return + selected continued post-November 2022 deleveraging + selected potential post-deleveraging dividend acceleration.
